Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma

NCT00670358 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00670358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00670358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
August 25, 2008
Completion date
October 4, 2024
Enrollment
138 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma